AGP Picks
View all

Technology News Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology News Journal.

Press releases published on November 10, 2026

Aro Biotherapeutics Reports Therapeutic Potential of Centyrin–CD40 siRNA Conjugate for the Treatment of Inflammatory Myositis
Big Sky Industrial Inc. Reports Third Quarter 2026 Results and Highlights Phase 1 Construction Progress at Big Sky Carbon Hub
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
Anaptys Announces Participation in Upcoming Investor Conferences
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Enviri Launches 2025 Impact Report
Marchex Returns to Revenue Growth and Profitability in Third Quarter 2026
NanoXplore Reports First Quarter Fiscal 2027 Results with Revenue up 36% and Begins Commercial Graphene Supply to Lead Insulating Foam Customer
NanoXplore annonce ses résultats pour T1-2027 avec une hausse de 36% du chiffres d’affaires et le début de la fourniture commerciale de graphène à un client de mousse isolante de premier plan
Firefly Aerospace Announces Third Quarter 2026 Financial Results With Record Backlog of $1.7 Billion
Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Rigetti Computing Reports Third Quarter 2026 Financial Results
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
SenesTech Reports Record Q3 2026 Revenue with 59% Year-Over-Year Growth
GigaCloud Technology Inc to Participate in Three Upcoming Investor Conferences
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Technology News Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.